GLP-1 receptor agonists (GLP-1 RAs) have been shown to reduce the incidence of major adverse cardiovascular events (MACEs) in patients with Type 2 Diabetes Mellitus [4]. Here, GCG is linked to type 2 diabetes mellitus.